Objective: To investigate the relationship between phosphoglycerate kinase 1 (PGK1) and clinicopathological parameters of breast cancer and its prognostic significance. Methods: (1)The matrix data and clinical data of PGK 1 mRNA expression in breast cancer and normal breast tissues were downloaded from TCGA and GEO databases. The relationship between PGK 1 mRNA expression in breast cancer tissues and clinicopathological features was analyzed. Logistics regression was used to evaluate the independent risk factors of PGK 1 mRNA expression. Kaplan-Meier method was used to draw survival curves to analyze the relationship between PGK 1 mRNA expression level and overall survival (OS) of breast cancer patients. (2)From January 2022 to January 2023, 50 cases of breast cancer and normal breast tissue specimens were collected from the Department of Breast Surgery, the First Affiliated Hospital of Baotou Medical College. The expression levels of PGK1 in breast cancer and normal breast tissues were detected by real-time fluorescence quantitative PCR and immunohistochemical staining, respectively. The relationship between PGK 1 expression and clinicopathological parameters in breast cancer tissues was analyzed, and Logistics regression was used to evaluate the independent risk factors related to PGK1 expression. Results: (1)The expression of PGK1 mRNA in breast cancer was significantly higher than that in normal breast tissue (P＜0.05). (2)ER, PR and HER-2 were independent risk factors for PGK1 mRNA expression. (3)The high expression of PGK 1 mRNA was positively correlated with the decrease of overall survival. (4)The expression of PGK 1 in breast cancer was statistically significant. (5)ER, PR and HER-2 were independent risk factors affecting the expression of PGK1. Conclusion: (1)The expression level of PGK1 in breast cancer is significantly increased. (2)The expression of ER, PR, HER-2 is positively correlated with the expression of PGK1. (3) High expression of PGK1 may be a potential predictor of poor prognosis of breast cancer.
JIA Wei
,
HE Tao
,
WANG Weitao
,
BAI Ziyao
. Study on the relationship between phosphoglycerate kinase 1 and breast cancer[J]. Journal of Baotou Medical College, 2025
, 41(3)
: 90
-96
.
DOI: 10.16833/j.cnki.jbmc.2025.03.016
[1] Katsura C, Ogunmwonyi I, Kankam HK, et al. Breast cancer: Presentation, investigation and management[J]. Br J Hosp Med (Lond). 2022 Feb 2;83(2):1-7.
[2] 王鹏.基于公共数据库的HMGCR表达与乳腺癌的相关研究[D].郑州:郑州大学,2020.
[3] 李颖,刘强. 乳腺癌的免疫治疗进展[J]. 临床外科杂志,2019,27(3):187-190.
[4] Fu Q, Yu ZH. Phosphoglycerate kinase 1 (PGK1) in cancer: A promising target for diagnosis and therapy[J]. Life Sci, 2020,256:117863.
[5] Liu H, Wang XC, Shen PB, et al. The basic functions of phosphoglycerate kinase 1 and its roles in cancer and other diseases[J]. Eur J Pharmacol, 2022,920:174835.
[6] Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China[J]. Lancet Oncol, 2014,15(7):e279-e289.
[7] Dias AS, Almeida CR, Helguero LA, et al. Metabolic crosstalk in the breast cancer microenvironment[J]. Eur J Cancer, 2019,121:154-171.
[8] Vaupel P, Multhoef G. Revisiting the Warburg effect: historical dogma versus current understanding[J]. J Physiol, 2021,599(6):1745-1757.
[9] He Y, Luo Y, Zhang D, et al. PGK1-mediated cancer progression and drug resistance[J]. Am J Cancer Res, 2019,9(11):2280-2302.
[10] Chen YY, Cen LJ, Guo R, et al. Roles and mechanisms of phosphoglycerate kinase 1 in cancer[J]. Bull Cancer, 2022,109(12):1298-1307.
[11] 张岚,王英聪,谢晓莺,等. 磷酸甘油酸激酶1对肝癌细胞侵袭转移及肝癌预后的影响[J]. 中华肝脏病杂志,2017,25(6):446-451.
[12] Ahmad SS, Glatzle J, Bajaeifer K, et al. Phosphoglycerate kinase 1 as a promoter of metastasis in colon cancer[J]. Int J Oncol, 2013,43(2):586-590.
[13] Wang JH, Wang JC, Dai JL, et al. A glycolytic mechanism regulating an angiogenic switch in prostate cancer[J]. Cancer Res, 2007,67(1):149-159.
[14] Lu W, Gao J, Yang JY, et al. Down-regulated phosphoglycerate kinase 1 expression is associated with poor prognosis in patients with gallbladder cancer[J]. Medicine, 2015,94(49):e2244.
[15] Hou YJ, Peng Y, Li ZB. Update on prognostic and predictive biomarkers of breast cancer[J]. Semin Diagn Pathol, 2022,39(5):322-332.
[16] Yip C H, Rhodes A. Estrogen and progesterone receptors in breast cancer[J]. Future Oncol, 2014,10(14):2293-2301.
[17] Li Y, Wang SS, Zhang XY, et al. Expression characteristics and significant prognostic values of PGK1 in breast cancer[J]. Front Mol Biosci, 2021,8:695420.
[18] Li WH, Xu M, Li Y, et al. Comprehensive analysis of the association between tumor glycolysis and immune/inflammation function in breast cancer[J]. J Transl Med, 2020,18(1):92.
